Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

Stroke

Volumn 28, Issue 5, 1997, Pages 946-950

  Blauw, Gerard J ^a   Lagaay, A Margot ^b   Smelt, Augustinus H M ^b   Westendorp, Rudi G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Leiden University Medical Centre ^*

Author keywords

cholesterol; HMG CoA reductase inhibitors; meta analysis; stroke prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 0031005723     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.5.946     Document Type: Article

References (30)

1. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
2. Glasser SP, DiBianco R, Effron BA, Faas F, Germino FW, Shane LE, Unger AH, Staggers JE. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol >160 mg/dL. Am J Cardiol. 1996;77:83-87.
3. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, for the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
4. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/L (200 to 300 mg/dL) plus two atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
5. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME for the PLAC I Investigators. Pravastatin limitations of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:133-139.
6. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol. 1995;75:455-459.
7. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995; 92:2419-2425.
8. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probsfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
9. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, for the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
10. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
11. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, O'Neill WW, Frazier JE, Cohen-Bernstein CL, Robbins DC, Brown CL III, Alexander RW, for the Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary anaplasty. N Engl J Med. 1994;331:1331-1337.
12. MAAS Investigators. Effect of simvastatin on coronary a atheroma. the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344: 633-638.
13. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
14. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow up. Am J Cardiol. 1994; 74:667-673.
15. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.
18. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
19. LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol. 1995;76:474-479.
20. Keech A, Collins R, McMahon S, Armitage J, Lawson A, Walledszus K, Fatemian M, Kearney E, Lyon V, Mindell J, Mount J, Painter R, Parish S, Slavin B, Sleight P, Youngman L, Peto R, for the Oxford Cholesterol Study Group. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994;15:255-269.
21. 2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol. 1995;15:759-764.
22. Chvlack LT, Mantell G, Wolff JK, Friends J, Rosner B. Lovastatin and the human lens: results of a two-year study. Optom Vis Sci. 1993;70:937-943.
23. Nozaki S, Vega GL, Haddox RJ, Dolan ET, Grundy SM. Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis. 1990;84:101-110.
24. Vega GL, Grundy SM. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA. 1989;262:3148-3153.
25. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1652.
26. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevolate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347: 102-103.
27. 1 cells. FEBS Lett. 1995;361:46-50.
28. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
29. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, Novick AC. Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol. 1996;156:249-252.
30. Scandinavian Simvastatin Survival Study Group. Baseline cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.